SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SANGUINE CORP. (SGNC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Hyrulean King who wrote (2358)7/2/1998 9:26:00 PM
From: Mr. Forthright  Read Replies (4) of 5402
 
The first four questions for the valuation model were:

1) What is the total market potential for synthetic red blood cell products?

2) What kind of market share/penetration is SGNC expected to achieve?

3) When is SGNC's product expected to get to market?

4) How many shares will be outstanding the year the product hits markets and in each of the following 5 years?

Here are a few more:

5) What is the expected growth rate for the 5 year period following the introduction of the product into the market?

6) What will SGNC net earnings after-tax (per share) be for those years. (Take into account the expenses, R&D costs and the fact that, if the product gets to market, the company is likely to earn a royalty on the sale of the product). In other words multiplying the answer to question 1 by the answer to question 2 does not equal the answer to question 6.

7) What P/E ratio would be appropriate to use for those years?

8) What discount rate would be appropriate to use to obtain a net present value?

More tomorrow.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News